BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30811720)

  • 21. BRAF p.V600E Mutational Status Does Not Correlate with Biological Behavior in Conventional Ameloblastomas: A Disease-Free Survival Analysis.
    Martins-de-Barros AV; da Costa Araújo FA; Faro TF; de Aquino AAT; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; de Oliveira E Silva ED; de Vasconcelos Carvalho M
    Head Neck Pathol; 2024 Mar; 18(1):23. PubMed ID: 38504068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients.
    Soltani M; Tabatabaiefar MA; Mohsenifar Z; Pourreza MR; Moridnia A; Shariati L; Razavi SM
    J Oral Pathol Med; 2018 Jan; 47(1):86-90. PubMed ID: 28650588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
    Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
    Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta-analysis.
    Martins-de-Barros AV; Silva CCG; Gonçalves KKN; de Albuquerque Cavalcanti Almeida R; de Oliveira E Silva ED; da Costa Araújo FA; Robinson L; van Heerden WFP; de Vasconcelos Carvalho M
    J Oral Pathol Med; 2023 Sep; 52(8):701-709. PubMed ID: 37364158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
    Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
    J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
    Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
    Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: Systematic review and meta-analysis.
    Martins-de-Barros AV; Anjos RSD; Silva CCG; Silva EDOE; Araújo FADC; Carvalho MV
    J Oral Pathol Med; 2022 Mar; 51(3):223-230. PubMed ID: 35090195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Mutational Profile of Unicystic Ameloblastoma.
    Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
    J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres.
    Bonacina R; Indini A; Massazza G; Rulli E; Gianatti A; Mandalà M;
    J Clin Pathol; 2022 Aug; 75(8):555-559. PubMed ID: 33827932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking.
    Guan P; Wong SF; Lim JQ; Ng CCY; Soong PL; Sim CQX; Ong CK; Rajasegaran V; Myint SS; Lee JY; Tan HK; Iyer NG; Soo KC; Teh BT; Tay ABG
    J Dent Res; 2019 Jun; 98(6):652-658. PubMed ID: 30917298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of BRAF V600E immunohistochemistry in the diagnosis of mandibular ameloblastomas.
    Ji YD; Johnson DN; Faquin WC; Peacock ZS
    Int J Oral Maxillofac Surg; 2024 Feb; 53(2):122-126. PubMed ID: 37344275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study.
    Shirsat PM; Bansal S; Prasad P; Desai RS
    J Oral Maxillofac Pathol; 2018; 22(3):353-359. PubMed ID: 30651680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration.
    Hirschhorn A; Campino GA; Vered M; Greenberg G; Yacobi R; Yahalom R; Barshack I; Toren A; Amariglio N; Rechavi G
    J Tissue Eng Regen Med; 2021 Dec; 15(12):1155-1161. PubMed ID: 34599642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. It was not possible to detect BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma: A diagnostic accuracy study.
    Martins-de-Barros AV; da Costa Araújo FA; Barros AMI; Dos Santos EGF; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; Neves RFSN; de Hollanda Valente RO; de Oliveira E Silva ED; de Vasconcelos Carvalho M
    J Oral Pathol Med; 2024 Apr; 53(4):258-265. PubMed ID: 38494749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High frequency of BRAF V600E mutations in ameloblastoma.
    Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
    J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic study on a rare variant of ameloblastoma with basal cell features.
    You Z; Sun L; Yan X; Zhang J; Du J; Li T; Zhao H
    Oral Dis; 2019 Apr; 25(3):788-795. PubMed ID: 30561173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
    Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.
    Zhang X; Wang L; Wang J; Zhao H; Wu J; Liu S; Zhang L; Li Y; Xing X
    Exp Mol Pathol; 2018 Aug; 105(1):153-159. PubMed ID: 30009773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.